Observes people with hypertrophic cardiomyopathy in France over time
Follows adults and teens in France who have hypertrophic cardiomyopathy, a heart thickening disease.
Plain-language title generated from the registry record
Registry title: French Hypertrophic Cardiomyopathy Observatory
Key facts
- Where
- Paris, FranceSee the site
Where in France
- European Georges Pompidou HospitalParis, FranceTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- French Cardiology Society
- Trial code
- NCT01091480
- Record updated
- 21 September 2022
- Original description
Hypertrophic cardiomyopathy (Hypertrophic CardioMyopathy=HCM) remains a poorly understood disease with an assumption insufficiently codified. There is no data available in France on the profile of patients, diagnostic methods and assessment and therapeutic use.Read full original descriptionShow less
French Hypertrophic Cardiomyopathy Observatory
Hypertrophic cardiomyopathy (Hypertrophic CardioMyopathy=HCM) remains a poorly understood disease with an assumption insufficiently codified. There is no data available in France on the profile of patients, diagnostic methods and assessment and therapeutic use.
The purpose of this study is to establish a monitoring of patients with HCM (sarcomere of origin or not) in France (diagnosis, treatment)
Inclusion: Age ≥ 15 years old; Patient with HCM defined by an ultrasound thickness of the left ventricle ≥ 13 mm if familial or ≥ 15 mm if sporadic.
Exclusion: Expressed refusal to participate in the study; Significant aortic stenosis (<1 cm ²).